We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Coagulation Tests Affected by Sodium Citrate Concentration

By LabMedica International staff writers
Posted on 27 Aug 2018
Print article
Image: The STA COMPACT MAX 2 is a fully automated benchtop analyzer (Photo courtesy of Diagnostica Stago).
Image: The STA COMPACT MAX 2 is a fully automated benchtop analyzer (Photo courtesy of Diagnostica Stago).
Despite a high degree of standardization, coagulation tests largely depend on preanalytic factors. Apart from artifacts acquired during blood drawing and transportation, the in vitro anticoagulant used has a potential impact on the coagulation test result.

Usually, a 9:1 blood to sodium citrate ratio is used with a buffer range between 3.2% and 3.8%.The 3.2% buffered sodium citrate binds less assay-added calcium than 3.8% buffered sodium citrate, therefore clotting times tend to be shorter in 3.2% than 3.8% buffered sodium citrate. Although there are no exact data available, today 3.2% buffered citrate is widely used.

Medical Laboratory Scientists at the Medical University of Vienna (Vienna, Austria) carried out a prospective observational study with 76 volunteers, differences related to the citrate concentration were evaluated. For both buffer concentrations, reference range intervals were established. Using the same calibration settings, 3.2% and 3.8% buffered citrate samples were consecutively analyzed. The reagent-analyzer combinations were chosen with respect to measurement accuracy and validity, assays' robustness and practicability during the parameters' introduction phase at their laboratory.

The activated partial thromboplastin time lupus-sensitive reagent (aPTT-LA) for lupus anticoagulant (LAC) confirmation testing was analyzed by using plasma with and without a reagent containing phosphatidylethanolamine. Lupus anticoagulant confirmation testing was considered positive when the difference between both aPTT-LA clotting times was greater than eight seconds or the ratio between the neat diluted Russell viper venom time (dRVVT) and the dRVVTConfirm (dRVVTRatio, Staclot DRVV Screen/Staclot DRVV Confirm) was greater than 1.25.

The team found that most parameters evaluated presented good comparability between citrated samples taken with 3.2% and 3.8% trisodium buffer. The ellagic acid containing activated partial thromboplastin time reagent (aPTT-FS) indicated a systemic and proportional difference between both buffer concentrations, leading to an alteration in its reference ranges. Further, a confirmation test for lupus anticoagulant assessment (Staclot LA) showed only a moderate correlation with a proportional deviation between both citrate concentrations. Further, a statistically significant difference was found in the diluted Russell viper venom time confirmation testing, coagulation factors V and VIII, and the protein C activity, which was found to be of minor clinical relevance.

The authors concluded that the alteration of 3.2% and 3.8% buffered sodium citrate on specialized coagulation tests in their setting was of limited relevance. As an exception, the aPTT-FS and aPTT-LADifference were significantly affected by the citrate concentration used. These findings demonstrate the comparability of data assessed with these citrate concentration ranges. The study was published in the August 2018 issue of the journal Archives of Pathology & Laboratory Medicine.

Related Links:
Medical University of Vienna

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
New
Biological Indicator Vials
BI-O.K.

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.